Clinical experience with three combination regimens for the treatment of high-risk febrile neutropenia

Basit Öğe Kaydı
dc.authoridErsoy, Yasemin/0000-0001-5730-6682
dc.authoridKAYA, Emin/0000-0001-8605-8497;
dc.authorwosidErsoy, Yasemin/AAE-4811-2020
dc.authorwosidKAYA, Emin/W-2951-2017
dc.authorwosidşerefhanoğlu, kıvanç/AAV-4737-2021
dc.contributor.authorSerefhanoglu, K
dc.contributor.authorErsoy, Y
dc.contributor.authorSerefhanoglu, S
dc.contributor.authorAydogdu, I
dc.contributor.authorKuku, I
dc.contributor.authorKaya, E
dc.date.accessioned2024-08-04T20:15:23Z
dc.date.available2024-08-04T20:15:23Z
dc.date.issued2006
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIntroduction: The objective of this study was to compare the safety and efficacy of ceftazidime (2 g every 8 h), piperacillin/tazobactam (4 g/500 mg every 6 h), and meropenem (1 g every 8 h), when combined with amikacin (15 mg/kg once daily), in the empirical treatment of high-risk febrile neutropenic episodes in patients with haematological malignancy. Materials and Methods: A prospective, comparative study designed in the haematology unit of a university hospital in Turkey. Results: A total of 89 febrile episodes in 60 neutropenic patients were treated; 29 febrile episodes in 23 patients with ceftazidime plus amikacin (group 1), 30 episodes in 25 patients with piperacillin/tazobactam plus amikacin (group 2), and 30 episodes in 25 patients with meropenem plus amikacin (group 3). The 3 groups were comparable in terms of age, sex, underlying malignancy, pretherapy neutrophil counts, duration of neutropenia and types of infections. Neutropenia, since the start of fever, persisted for >= 10 days in all of the episodes in the 3 study groups. Nearly all of the episodes were seen in patients with acute leukaemia. In 25.8% (23/89) of the febrile neutropenia episodes, an aetiologic organism was isolated, with gram-negative bacteria being the most commonly isolated. The success without modification rates were 34.5%, 30% and 36.7% for groups 1, 2 and 3, respectively (P > 0.05). After modification with a different class of antimicrobial therapy, the response rates increased to 65.5%, 63.3% and 70% for groups 1, 2 and 3, respectively (P > 0.05). The mean duration of treatment and the time to defervescence were also comparable in all groups. In all arms, side effects were minimal. Conclusions: It is concluded that the 3 regimens were equally effective and safe in the empirical treatment of high-risk febrile neutropenic episodes.en_US
dc.identifier.endpage16en_US
dc.identifier.issn0304-4602
dc.identifier.issue1en_US
dc.identifier.pmid16470268en_US
dc.identifier.scopus2-s2.0-33645835394en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage11en_US
dc.identifier.urihttps://hdl.handle.net/11616/94354
dc.identifier.volume35en_US
dc.identifier.wosWOS:000236512600004en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAcad Medicine Singaporeen_US
dc.relation.ispartofAnnals Academy of Medicine Singaporeen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectantibiotic therapyen_US
dc.subjecthaematological malignancyen_US
dc.titleClinical experience with three combination regimens for the treatment of high-risk febrile neutropeniaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu